Ten Berge R E, Weening E C, Roffel A F, Zaagsma J
Groningen/Utrecht Institute for Drug Exploration, Department of Medicinal Chemistry and Molecular Pharmacology, University of Groningen, Netherlands.
Eur J Pharmacol. 1995 Mar 6;275(2):199-206. doi: 10.1016/0014-2999(94)00771-x.
We studied the effects of selective beta-adrenoceptor agonists on the cholinergic and non-adrenergic non-cholinergic (excitatory NANC) contractions elicited by electrical field stimulation of guinea pig main bronchi in vitro. Addition of the selective beta 2-adrenoceptor agonists, fenoterol and salbutamol, and the selective beta 3-adrenoceptor agonist, BRL 37344 (4-[2-[(2-hydroxy-2-(3-chlor-phenyl)ethyl)amino]-propyl]-phenoxyac etic acid), induced a dose-dependent inhibition of the cholinergic contraction (pD2 7.89, 6.71 and 4.56, respectively) and the excitatory NANC response (pD2 9.11, 8.16 and 7.42, respectively). Fenoterol- and BRL 37344-induced inhibition of the excitatory NANC response was blocked with high potency (pKB 8.77 and 9.07, respectively) by the selective beta 2-adrenoceptor antagonist, ICI 118,511 (erythro-1-(7-methylindan-4-yloxy)-3-(isopropylamino)-but an-2-ol). A comparable contraction induced by neurokinin A (2 or 5 nM) was also inhibited by fenoterol, salbutamol and BRL 37344, but at significantly higher concentrations than for the inhibition of the excitatory NANC response (pD2 8.72, 7.56 and 6.66, respectively). Such a preferential inhibition of electrical field stimulation- versus agonist-induced effects was not observed for cholinergic contractions (pD2 versus methacholine-induced tone 7.86, 6.93 and 5.10, respectively). The results clearly exclude the involvement of beta 3-adrenoceptors in these responses. Furthermore they show that beta 2-adrenoceptors are involved in the prejunctional inhibition of excitatory NANC contractions, presumably via modulation of tachykinin release from sensory nerves, and solely in the postjunctional inhibition of cholinergic contractions.
我们研究了选择性β-肾上腺素能受体激动剂对豚鼠主支气管体外电场刺激所引发的胆碱能及非肾上腺素能非胆碱能(兴奋性非肾上腺素能非胆碱能,excitatory NANC)收缩的影响。添加选择性β₂-肾上腺素能受体激动剂非诺特罗和沙丁胺醇,以及选择性β₃-肾上腺素能受体激动剂BRL 37344(4-[2-[(2-羟基-2-(3-氯苯基)乙基)氨基]-丙基]-苯氧基乙酸),可诱导对胆碱能收缩(pD₂分别为7.89、6.71和4.56)及兴奋性NANC反应(pD₂分别为9.11、8.16和7.42)的剂量依赖性抑制。非诺特罗和BRL 37344诱导的对兴奋性NANC反应的抑制被选择性β₂-肾上腺素能受体拮抗剂ICI 118,511(赤藓醇-1-(7-甲基茚满-4-基氧基)-3-(异丙基氨基)-丁-2-醇)高效阻断(pKB分别为8.77和9.07)。神经激肽A(2或5 nM)诱导的类似收缩也被非诺特罗、沙丁胺醇和BRL 37344抑制,但所需浓度显著高于抑制兴奋性NANC反应的浓度(pD₂分别为8.72、7.56和6.66)。对于胆碱能收缩,未观察到这种对电场刺激与激动剂诱导效应的优先抑制(pD₂与乙酰甲胆碱诱导的张力相比分别为7.86、6.93和5.10)。结果明确排除了β₃-肾上腺素能受体参与这些反应。此外,结果表明β₂-肾上腺素能受体参与兴奋性NANC收缩的节前抑制,推测是通过调节感觉神经速激肽的释放,且仅参与胆碱能收缩的节后抑制。